NDx

PRECISION NEUROLOGY

AI-enabled multi-omic
blood tests for neurodegeneration

We turn a routine blood draw into a real-time readout of brain health.
So drug developers enroll the right patients and learn sooner whether a therapy works.

SEPT 2026

The Problem

The Measurement Gap in Neurodegenerative Diseases

— hampers drug development, clinical monitoring, and ultimately patient care.

The scope

57M

living with dementia · ~10M new cases/yearWHO

1,023

ongoing ND drug trials · 678 in Phase 2/3CT.gov

$1.3T

annual global cost of dementiaWHO

How we measure today

Amyloid PET

~$5,000 / scan

Too expensive and scanner-boundUSC

A lumbar puncture performed through a sterile drape

CSF / lumbar puncture

75% → 64%

Invasive — drops enrollment willingnessPMC

A hand holding several blood collection tubes

Plasma pTau217

1 analyte

Amyloid only, AD only — doesn't generalizeFDA

Who pays for it

Clinicians

3 in 4 dementia cases go undiagnosed — and no objective way to monitorADI

Patients

Months of waiting before a symptom scale can register whether anything has changed

Drug developers

>70% screen-fail, then 12–18 mo to a clinical-scale readoutAlz&Dem

One root cause across every disease: no scalable, longitudinal readout of brain biology.

Images via Wikimedia Commons — PET: U.S. Navy, public domain · LP: Dragondefuego1976, CC BY-SA 4.0 · Tubes: Tannim101, CC BY 3.0

The solution

One blood draw, one AI engine,
two scores pharma can act on

Plasma sample

Simple blood draw

Multi-omic data

Captures diverse cellular, epigenetic and immune signals

Multimodal AI integration

Adds intelligence and efficiency — fusing orthogonal signals into one interpretable signature

Biomarker signature

A richer disease signal than any single marker alone

Pre-screening score

Identifies likely trial-eligible patients

Longitudinal monitoring score

Tracks disease biology and therapeutic response over time

Universally accessible

Proprietary data

Agentic workflow

Biomarker Matrix

In-house model

We target neuronal death itself — a universal hallmark — not a single-disease hypothesis like amyloid or tau.

The same engine scales across Alzheimer's, Parkinson's, ALS and other neurodegenerative diseases.

An agentic pipeline runs the discovery cycle end to end.

Our current state

Multi-disease signal shown in a
completed two-year pilot

60

patients
completed 2-year pilot

3

diseases analysed
AD · PD · ALS

2

orthogonal
assay platforms

60-patient, 2-year longitudinal pilot completed

Initial multi-omic human dataset from standard blood draws

Core multi-omic workflows established

Automated AI-assisted analysis pipeline established

Stanford biobank collaborations in place

Stanford OTL invention disclosure filed

Signal extraction is demonstrated in human plasma across three diseases. Next is validation at scale — hundreds more samples across AD, PD and ALS.

Go to pharma

A screening, monitoring platform for pharma

1 · Pre-screening

Who should enter the trial?

Accessible, rapid, affordable blood test to screen patients for clinical trials.

1,000

candidates

NDx blood screen

all 1,000 candidates

~300

to PET

PET only confirms the shortlist.

PET ~$5,000

NDx blood ~$950

PET spend drops from 1,000 scans to ~300

Blood result in ~2 weeks

2 · Longitudinal monitoring

Is the drug working?

Objective, blood-based molecular monitoring of treatment effect.

Today · PET + CSF ~18 mo

With NDx · blood 6–12 wks

~15 mo

trial decision accelerated

~60%

reduction in test costs

Earlier treatment-effect signal means faster go / no-go

Per-sample pricing and savings are NDx models on stated assumptions.

Market

A big, open market with high growth

TAM · $12.8B / yr

All brain-disease diagnosis and monitoring

SAM · $5.05B / yr

Neurodegenerative disease specifically — AD, PD, ALS and related

SOM · $1.65B / yr

Our goal as the category leader — ~30% of SAM at maturity

The category just opened — FDA cleared the first Alzheimer's blood test in May 2025; Labcorp launched it nationwide that August.FDA FMI

And it compounds — blood-based AD biomarkers go $169M (2025) → $530M (2033), a 3.1× move.FMI

Capital is following — Gates is funding blood-based Alzheimer's diagnostics and calling for routine screening from age 60.Gates Notes

TAM is the global annual brain-disease diagnosis and monitoring market; SAM is the neurodegenerative-disease segment; the ~30% mature share is an NDx assumption · growth FMI · clearance FDA, May 2025 · demand signal Fortune, STAT.

The business model

Integrated Precision Medicine
Business Flywheel

1

Pharma servicesAccelerate trial enrollment · upfront + per-sample fees

2

Proprietary dataIn-house multi-omic pipeline · data licensing + insights

3

CDx partnershipsCo-develop targeted assays · clinical + regulatory milestones

4

Clinical testingFDA-cleared rollout to neurologists · recurring reimbursement

Accelerated Growth FlywheelEvery sample sharpens the next readout.

Revenue funds data · data improves the model · a better model wins the next contract.

Team

Built to take biomarkers from
discovery to clinics

Wet lab, computational biology and ML product — with the clinical access to run the study.

CEO

Ze Yang

Multi-omics & wet lab

Scientist, Stanford University
PhD, Stanford University

CTO

Daniel Zheng

AI & Product

Siri AI Engineer, Apple
Ex-CTO, Utopia Studios

CSO

Siyu He

AI & computational biology

Postdoc, Stanford University
PhD, Columbia University

Advisor

Kathleen Poston

Clinics & biomarkers

Professor of Neurology
Stanford Medicine

NDx

PRECISION NEUROLOGY

Building accessible AI for brain health.

yangze@stanford.edu

SEPT 2026

AI-enabled multi-omicblood tests for neurodegeneration

The Measurement Gap in Neurodegenerative Diseases

One blood draw, one AI engine,two scores pharma can act on

Multi-disease signal shown in acompleted two-year pilot